Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2

被引：0
|
作者：
Rheault, T. [1 ]
Bengtsson, T. [2 ]
Rickard, K. [3 ]
机构：
[1] Verona Pharma, Cary, NC USA
[2] StatMind AB, Lund, Sweden
[3] Verona Pharma, Raleigh, NC USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5000
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
    Anzueto, Antonio
    Barjaktarevic, Igor Z.
    Siler, Thomas M.
    Rheault, Tara
    Bengtsson, Thomas
    Rickard, Kathleen
    Sciurba, Frank
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (04) : 406 - 416
  • [32] Improvements in health-related quality of life and symptoms of depression with tofacitinib: Results from two randomized phase 3 studies in patients with moderate to severe psoriasis
    Thaci, Diamant
    Griffiths, Christopher E. M.
    Bundy, Christine
    Korman, Neil J.
    Lan, Shuping
    Robertson, Deborah
    Tatulych, Svitlana
    Tallman, Anna
    Kaur, Mandeep
    Mamolo, Carla
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB255 - AB255
  • [33] Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, controlled trial (ESTEEM 1)
    Papp, Kim A.
    Reich, Kristian
    Sobell, Jeffrey M.
    Menter, Alan
    Lacour, Jean-Philippe
    Chimenti, Sergio
    Hu, ChiaChi
    Day, Robert M.
    Shah, Kamal
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB256 - AB256
  • [34] Ixekizumab impact on health-related quality of life compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis
    Reich, Kristian
    Toth, Darryl
    Nikai, Enkeleida
    Zhu, Baojin
    Carlier, Hilde
    Feldman, Steven
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S35 - S35
  • [35] Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial
    Bafadhel, M.
    Christenson, S. A.
    Hanania, N. A.
    Bhatt, S. P.
    Rabe, K. F.
    Vogelmeier, C. F.
    Papi, A.
    Singh, D.
    Laws, E.
    Nivens, C.
    Bansal, A.
    Lu, X.
    Bauer, D.
    Maloney, J.
    Robinson, L. B.
    Abdulai, R. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [36] The Relationship Between Chronic Constipation Symptoms and Health-Related Quality of Life: Results From 2 Phase 3 Trials
    Taylor, Douglas C.
    Buono, Jessica L.
    Spalding, William M.
    Carson, Robyn
    GASTROENTEROLOGY, 2014, 146 (05) : S193 - S193
  • [37] Ustekinumab Improves General Health Status and Disease-Specific Health Related Quality of Life of Patients with Moderate to Severe Crohn's Disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials
    Sands, Bruce E.
    Han, Chenglong
    Gasink, Christopher
    Szapary, Philippe
    Gao, Long-Long
    Lang, Yinghua
    Feagan, Brian G.
    GASTROENTEROLOGY, 2016, 150 (04) : S1004 - S1004
  • [38] Improvement in sleep is associated with improved quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a phase 3 trial of baricitinib therapy
    Lio, Peter
    Han, George
    Lain, Edward
    Maari, Catherine
    Ball, Susan
    Sun, Luna
    DeLozier, Amy M.
    Buchanan, Andrew
    Ding, Yuxin
    Eichenfield, Lawrence F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB14 - AB14
  • [39] Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy
    Lio, Peter A.
    Simpson, Eric L.
    Han, George
    Soung, Jennifer
    Ball, Susan
    Sun, Luna
    Casillas, Marta
    DeLozier, Amy M.
    Ding, Yuxin
    Eichenfield, Lawrence F.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2057 - 2062
  • [40] Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
    Ohtsuki, Mamitaro
    Okubo, Yukari
    Komine, Mayumi
    Imafuku, Shinichi
    Day, Robert M.
    Chen, Peng
    Petric, Rosemary
    Maroli, Allan
    Nemoto, Osamu
    JOURNAL OF DERMATOLOGY, 2017, 44 (08): : 873 - 884
12345